- Home
- TRGP vs EW Comparison
TRGP vs EW Comparison
Compare TRGP & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRGP | EW |
|---|---|---|
| Founded | 2005 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1B | 50.2B |
| IPO Year | 2010 | 1999 |
Fundamental Metrics
Financial Performance| Metric | TRGP | EW |
|---|---|---|
| Price | $259.14 | $82.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $257.29 | $96.37 |
| AVG Volume (30 Days) | 1.1M | ★ 5.1M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 47.91 | N/A |
| EPS | ★ 8.49 | 1.83 |
| Revenue | ★ $17,028,300,000.00 | $6,067,600,000.00 |
| Revenue This Year | $30.33 | $13.39 |
| Revenue Next Year | $6.55 | $9.81 |
| P/E Ratio | ★ $29.34 | $44.39 |
| Revenue Growth | 3.95 | ★ 11.55 |
| 52 Week Low | $144.14 | $72.30 |
| 52 Week High | $253.87 | $87.89 |
Technical Indicators
Market Signals| Indicator | TRGP | EW |
|---|---|---|
| Relative Strength Index (RSI) | 70.80 | 55.09 |
| Support Level | $231.90 | $80.91 |
| Resistance Level | N/A | $87.22 |
| Average True Range (ATR) | 5.23 | 2.18 |
| MACD | 1.50 | 0.40 |
| Stochastic Oscillator | 98.42 | 74.90 |
Price Performance
Historical ComparisonAbout TRGP Targa Resources Inc.
Targa Resources is a midstream firm that primarily operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.